Bethesda, Md. – AABB will hold a complimentary webinar to highlight recommendations for optimizing the use of plasma components, particularly group AB plasma, which is often in high demand. The practices to be described during the webinar are important in light of a new requirement in the association’s 29th edition of Standards for Blood Banks and Transfusion Services that calls for the implementation of transfusion-related acute lung injury, or TRALI, risk reduction measures for plasma and whole blood for transfusion. The standard becomes effective on April 1, 2014. This webinar will be conducted on March 27, 2014, from 2:00-3:30 pm ET.
“Numerous studies have documented that a TRALI risk mitigation strategy using some or all of the interventions specified in Standard 188.8.131.52 will substantially reduce TRALI incidence from allogeneic plasma transfusion,” said AABB Chief Executive Officer Miriam A. Markowitz. “AABB promulgated the new requirement following thoughtful and thorough discussions among scientific leaders and subject matter experts about how to most effectively address this complex patient safety issue.”
AABB Standard 184.108.40.206 requires that “plasma and whole blood for allogeneic transfusion shall be from males, females who have not been pregnant, or females who have been tested since their most recent pregnancy and results interpreted as negative for HLA antibodies.”
AABB’s standard-setting process is focused on helping to ensure the safety and adequacy of the blood supply, and the association is producing this webinar to assist its members and other hospitals in alleviating a potential impact on the availability of plasma, particularly group AB plasma.
The March 27 webinar will be conducted by:
- Steven Kleinman, MD
Senior Medical Advisor
- Kevin Land, MD
Senior Medical Director, Field Operations
- Mark Yazer, MD
Associate Professor of Pathology at the University of Pittsburgh
Medical Director, RBC Serology Reference Laboratory and Associate Medical Director at Centralized Transfusion Service
To register for the webinar and view speaker bios, visit:
www.aabb.org > Meetings & Events > Webinar - Suggestions for Optimizing Use of Plasma in the Era of TRALI Risk Reduction.
An August 2013 “Transfusion” article co-authored by Land, Yazer and Anne F. Eder, MD, PhD, describes group AB plasma usage trends: http://onlinelibrary.wiley.com/doi/10.1111/trf.12223/pdf.
Since 1957, AABB has been a leader in the development of standards for voluntary compliance in blood bank blood component collection, processing and transfusion. In the years since, AABB standards-setting programs have expanded to encompass several new disciplines. In addition to the Standards for Blood Banks and Transfusion Services, AABB now publishes Standards for Cellular Therapy Product Services (including hematopoietic progenitor cells, somatic cells and cord blood), Standards for Immunohematology Reference Laboratories, Standards for Relationship Testing Laboratories (formerly Standards for Parentage Testing Laboratories), Standards for Perioperative Autologous Blood Collection and Administration, and Standards for Molecular Testing for Red Cell, Platelet, and Neutrophil Antigens.
AABB is an international, not-for-profit association representing individuals and institutions involved in the field of transfusion medicine and cellular therapies. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety. AABB membership consists of nearly 2,000 institutions and 8,000 individuals, including physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. Members are located in more than 80 countries. For more information, visit www.aabb.org.